[go: up one dir, main page]

DE69926794D1 - Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen - Google Patents

Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen

Info

Publication number
DE69926794D1
DE69926794D1 DE69926794T DE69926794T DE69926794D1 DE 69926794 D1 DE69926794 D1 DE 69926794D1 DE 69926794 T DE69926794 T DE 69926794T DE 69926794 T DE69926794 T DE 69926794T DE 69926794 D1 DE69926794 D1 DE 69926794D1
Authority
DE
Germany
Prior art keywords
ponazuril
abortigenic
coccidia
neurological
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926794T
Other languages
English (en)
Other versions
DE69926794T2 (de
Inventor
J Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of DE69926794D1 publication Critical patent/DE69926794D1/de
Publication of DE69926794T2 publication Critical patent/DE69926794T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69926794T 1998-12-22 1999-12-18 Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen Expired - Lifetime DE69926794T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US218323 1980-12-19
US09/218,323 US6150361A (en) 1998-12-22 1998-12-22 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
PCT/US1999/030281 WO2000037063A2 (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma

Publications (2)

Publication Number Publication Date
DE69926794D1 true DE69926794D1 (de) 2005-09-22
DE69926794T2 DE69926794T2 (de) 2006-01-19

Family

ID=22814646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926794T Expired - Lifetime DE69926794T2 (de) 1998-12-22 1999-12-18 Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen

Country Status (17)

Country Link
US (1) US6150361A (de)
EP (1) EP1140103B1 (de)
JP (1) JP2002532544A (de)
KR (1) KR100661111B1 (de)
CN (1) CN1221265C (de)
AT (1) ATE302011T1 (de)
AU (1) AU764608B2 (de)
BR (1) BR9916391A (de)
CA (1) CA2355825C (de)
DE (1) DE69926794T2 (de)
DK (1) DK1140103T3 (de)
ES (1) ES2247863T3 (de)
HK (1) HK1045266B (de)
HU (1) HUP0104595A3 (de)
NZ (1) NZ512477A (de)
WO (1) WO2000037063A2 (de)
ZA (1) ZA200103920B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766542B2 (en) 1998-10-08 2003-10-16 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE19958388A1 (de) 1999-12-03 2001-06-07 Bayer Ag Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten
WO2001080885A2 (en) * 2000-04-25 2001-11-01 Wyeth Equine protozoal myeloencephalitis vaccine
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
DE102006038292A1 (de) * 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
WO2024138230A1 (en) * 2022-12-02 2024-06-27 Veterinary Pharmacy Corporation Formulation and method for treatment of infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) * 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
US4933341A (en) * 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5883095A (en) * 1997-08-07 1999-03-16 University Of Kentucky Research Foundation Formulations and methods to treat and prevent equine protozoal myeloencephalitis
CA2285477C (en) * 1997-03-31 2006-10-10 The University Of Kentucky Research Foundation Formulations and methods to treat and prevent equine protozoal myeloencephalitis
DE19824483A1 (de) * 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
AU766542B2 (en) * 1998-10-08 2003-10-16 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease

Also Published As

Publication number Publication date
JP2002532544A (ja) 2002-10-02
CA2355825C (en) 2008-07-08
AU2481700A (en) 2000-07-12
HUP0104595A2 (hu) 2002-04-29
AU764608B2 (en) 2003-08-28
DE69926794T2 (de) 2006-01-19
ZA200103920B (en) 2002-05-15
US6150361A (en) 2000-11-21
WO2000037063A3 (en) 2000-10-19
ES2247863T3 (es) 2006-03-01
KR100661111B1 (ko) 2006-12-26
WO2000037063A2 (en) 2000-06-29
DK1140103T3 (da) 2005-12-19
EP1140103A2 (de) 2001-10-10
ATE302011T1 (de) 2005-09-15
BR9916391A (pt) 2001-09-18
HK1045266A1 (en) 2002-11-22
HK1045266B (zh) 2006-07-07
KR20010080570A (ko) 2001-08-22
EP1140103B1 (de) 2005-08-17
NZ512477A (en) 2004-05-28
HUP0104595A3 (en) 2003-10-28
CA2355825A1 (en) 2000-06-29
CN1342081A (zh) 2002-03-27
CN1221265C (zh) 2005-10-05

Similar Documents

Publication Publication Date Title
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
RU94045155A (ru) Способы ингибирования болезни альцгеймера
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
ATE416164T1 (de) Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen
DE69918716D1 (de) Triazinoneverbindungen für die behhandlung von krankheiten verursacht durch neospora und toxoplasma
GB0130677D0 (en) Medicaments and novel compounds
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
NO993275D0 (no) FremgangsmÕte ved terapeutisk administrering av anti-CD40L-forbindelser
ATE125704T1 (de) Behandlung neurodegenerativer erkrankungen.
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
BR9916417A (pt) Compostos triazinaona para tratamento de doenças devidas à sarcosystis, neospora e toxoplasma
EP1050303A3 (de) Methoden und Zusammenstellungen zur Behandlung von altersgebundenen Verhaltensstörungen von Haustieren
DE60115237D1 (de) Praziquantel zusammensetzungen zur behandlung von krankheiten verursacht durch kokzidien
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF

Legal Events

Date Code Title Description
8364 No opposition during term of opposition